220 related articles for article (PubMed ID: 35028717)
21. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
22. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
23. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
25. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
26. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
27. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
Watts KJ; Meiser B; Mitchell G; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson M; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K;
BMC Cancer; 2012 Jul; 12():320. PubMed ID: 22838957
[TBL] [Abstract][Full Text] [Related]
28. Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer.
Gammon AD; Rothwell E; Simmons R; Lowery JT; Ballinger L; Hill DA; Boucher KM; Kinney AY
J Genet Couns; 2011 Dec; 20(6):625-38. PubMed ID: 21691939
[TBL] [Abstract][Full Text] [Related]
29. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
30. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
[TBL] [Abstract][Full Text] [Related]
31. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
32. Management of women at increased risk for hereditary breast cancer.
Smith KL; Isaacs C
Breast Dis; 2006-2007; 27():51-67. PubMed ID: 17917140
[TBL] [Abstract][Full Text] [Related]
33. A descriptive study of BRCA1 testing and reactions to disclosure of test results.
Lynch HT; Lemon SJ; Durham C; Tinley ST; Connolly C; Lynch JF; Surdam J; Orinion E; Slominski-Caster S; Watson P; Lerman C; Tonin P; Lenoir G; Serova O; Narod S
Cancer; 1997 Jun; 79(11):2219-28. PubMed ID: 9179070
[TBL] [Abstract][Full Text] [Related]
34. Uptake of genetic testing among patients seeking cancer genetic counseling in Taiwan.
Fang SY; Hsieh LL; Hung CF; Wang YA
J Genet Couns; 2024 Apr; 33(2):322-328. PubMed ID: 37194127
[TBL] [Abstract][Full Text] [Related]
35. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
36. Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
Sutton AL; Hurtado-de-Mendoza A; Quillin J; Rubinsak L; Temkin SM; Gal T; Sheppard VB
J Womens Health (Larchmt); 2020 Aug; 29(8):1131-1135. PubMed ID: 31794334
[No Abstract] [Full Text] [Related]
37. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
38. Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees.
van Driel CMG; Oosterwijk JC; Meijers-Heijboer EJ; van Asperen CJ; Zeijlmans van Emmichoven IA; de Vries J; Mourits MJE; Henneman L; Timmermans DRM; de Bock GH
Breast; 2016 Dec; 30():66-72. PubMed ID: 27639031
[TBL] [Abstract][Full Text] [Related]
39. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
40. BRCA mutation genetic testing implications in the United States.
Bayraktar S; Arun B
Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
